Recently, the results of a Phase 4 trial INHALE-3 study comparing inhalable insulin to current standard treatments in type 1 diabetes demonstrated that inhaled insulin (technosphere insulin, Afrezza, administered as a dry powder via a single puff) can be as effective as usual care while offering potential advantages in post-meal glucose control and patient preference (NCT05904743). Here, INS is linked to type 1 diabetes mellitus.